Available from stock

Crizotinib

SKU: C0699

Category: API's & Intermediates

Synonyms: (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine , PF 2341066 , PF-02341066 , PF02341066 , Xalkori; 877399-52-5
CAS-Number: C₂₁H₂₂Cl₂FN₅O
Molecular Formula: 450.34
Molecular Weight

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.

Product Data
Handling
Safety Information
Details

Specifications

Purity: ≥98% (HPLC)
Appearance: White to off-white powder
Identity: 1H-NMR

Properties

Solvents: choroform, DMSO, methanol

Shipping: AMBIENT
Short Term Storage: RT
Long Term Storage: +4°C
Handling Advice: Protect from light and moisture.
Use / Stability: Stable for at least 2 years after receipt when stored at +4°C.

Hazard statements: H317-H319-H341-H400
Precautionary statements: P273-P280-P305 + P351 + P338
GHS Symbol: GHS07+GHS08+GHS09
Signal word: Warning
RIDADR: UN 3077 9
Transportation: Packing Group III

Description: Crizotinib is an anticancer drug. It is a potent, orally bioavailable, ATP-competitive inhibitor of the receptor tyrosine kinases (RTKs) c-Met (hepatocyte growth factor receptor), anaplastic lymphoma kinase (ALK) and and ROS1 (c-ros oncogene 1). Selective for c-MET and ALK against >120 different kinases. Displays antitumor efficacy in multiple tumor models| inhibits c-MET-dependent proliferation, migration and invasion of human tumor cells in vitro. Orally bioavailable. Crizotinib was approved for treatment of a subtype of nonsmall-cell lung cancer (NSCLC) with ALK fusion mutations.
Smiles: NC1=NC=C(C2=CN(C3CCNCC3)N=C2)C=C1O[C@H](C)C4=C(Cl)C(F)=CC=C4Cl
InChi Key: KTEIFNKAUNYNJU-GFCCVEGCSA-N
References: (1) H.Y. Zou, et al., Cancer Res. 67, 4408 (2007) , (2) J.G. Christensen, et al., Mol. Cancer Ther. 6, 3314 (2007) , (3) J.J. Cui, et al., J. Med. Chem. 54, 6342 (2011) , (4) J. Tanizaki, et al., J. Thorac. Oncol. 6, 1624 (2011) , (5) Y. Yuan, et al., J. Hematol. Oncol. 4, 1 (2011) , (6) A.T. Shaw, et al., N. Engl. J. Med. 371, 1963 (2014)

Crizotinib is an anticancer drug. It is a potent, orally bioavailable, ATP-competitive inhibitor of the receptor tyrosine kinases (RTKs) c-Met (hepatocyte growth factor receptor), anaplastic lymphoma kinase (ALK) and and ROS1 (c-ros oncogene 1). Selective for c-MET and ALK against >120 different kinases. Displays antitumor efficacy in multiple tumor models| inhibits c-MET-dependent proliferation, migration and invasion of human tumor cells in vitro. Orally bioavailable. Crizotinib was approved for treatment of a subtype of nonsmall-cell lung cancer (NSCLC) with ALK fusion mutations.

SKU: C0699 Category: API's & Intermediates

Additional information

Additional information

Synonyms	(R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine, PF 2341066, PF-02341066, PF02341066, Xalkori
Purity	≥98% (HPLC)
Appearance	White to off-white powder
CAS-Number	877399-52-5
Molecular Formula	C21H22Cl2FN5O
Molecular Weight	450.34
Identity	1H-NMR
Solvents	choroform, DMSO, methanol
Smiles	NC1=NC=C(C2=CN(C3CCNCC3)N=C2)C=C1O[C@H](C)C4=C(Cl)C(F)=CC=C4Cl
InChi Key	KTEIFNKAUNYNJU-GFCCVEGCSA-N
Shipping	AMBIENT
Short Term Storage	RT
Long Term Storage	+4°C
Handling Advice	Protect from light and moisture.
Use / Stability	Stable for at least 2 years after receipt when stored at +4°C.
Hazard statements	H317-H319-H341-H400
Precautionary statements	P273-P280-P305 + P351 + P338
GHS Symbol	GHS07+GHS08+GHS09
Signal word	Warning
RIDADR	UN 3077 9
Transportation	Packing Group III
References	(1) H.Y. Zou, et al., Cancer Res. 67, 4408 (2007), (2) J.G. Christensen, et al., Mol. Cancer Ther. 6, 3314 (2007), (3) J.J. Cui, et al., J. Med. Chem. 54, 6342 (2011), (4) J. Tanizaki, et al., J. Thorac. Oncol. 6, 1624 (2011), (5) Y. Yuan, et al., J. Hematol. Oncol. 4, 1 (2011), (6) A.T. Shaw, et al., N. Engl. J. Med. 371, 1963 (2014)
Quantity	10 mg, 50 mg, Bulk